Current Treatment Options in Psychiatry

, Volume 5, Issue 4, pp 363–376 | Cite as

Thyroid Hormone Treatment of Mood Disorders

  • Fabrice DuvalEmail author
Mood Disorders (C Nemeroff and J Newport, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Mood Disorders


Purpose of review

Both excess and insufficient thyroid hormones can lead to depression that is generally reversible with adequate thyroid treatment. On the other hand, major depression is associated with subtle chronobiological hypothalamic-pituitary-thyroid (HPT) axis dysregulation and thyroid hormones can be an effective adjunct to antidepressant treatment. However, the links between HPT axis status and efficacy of thyroid hormone supplementation in depression remain to be further clarified.

Recent findings

While generally, depressed patients are chemically euthyroid, most exhibit a chronobiological HPT axis dysregulation (i.e., loss of the nocturnal thyrotropin [TSH] rise, blunted evening TSH response to protirelin [TRH], reduced difference in TSH response between 11 PM and 8 AM TRH tests [ΔΔTSH]), possibly associated with blunted 8 AM-TSH response to TRH and/or altered levels of circulating thyroxine (FT4) and triiodothyronine (T3). Usually, chronobiological HPT axis abnormalities are unrelated to increased cortisol levels. Normalization of thyroid function tests by antidepressants, especially the ΔΔTSH test, may occur before the clinical response. In patients who are resistant to antidepressants, there is good evidence for adjuvant therapy with thyroid hormones.


While there is a limited evidence base to guide long-term adjunctive use, thyroid hormone augmentation can be a safe and effective alternative treatment for euthyroid-depressed patients who receive appropriate baseline and follow-up safety monitoring. However, it remains to be established which bio-clinical subtypes of depression respond preferentially to thyroid hormone supplementation. In the next future, metabolically stable TRH analogs could be used in order to maintain or restore homeostasis, which is frequently disrupted in depressive states.


TRH TSH T4 T3 Antidepressants Augmentation Refractory depression 


Compliance with ethical standards

Conflict of interest

Fabrice Duval declares that he has no conflict of interest.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, et al. Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). Eur Neuropsychopharmacol. 2018;28:752–60. This multicenter study explored the association between depression and thyroid dysfunction.CrossRefPubMedGoogle Scholar
  2. 2.
    Dayan CM, Panicker V. Hypothyroidism and depression. Eur Thyroid J. 2013;2:168–79. Scholar
  3. 3.
    Jackson IM. The thyroid axis and depression. Thyroid. 1998;8:951–6. Scholar
  4. 4.
    Duval F, Macher JP, Mokrani MC. Difference between evening and morning thyrotropin responses to protirelin in major depressive episode. Arch Gen Psychiatry. 1990;47(5):443–8.CrossRefGoogle Scholar
  5. 5.
    • Duval F, Mokrani MC, Erb A, Gonzalez Lopera F, Alexa C, Proudnikova X, et al. Chronobiological hypothalamic-pituitary-thyroid axis status and antidepressant outcome in major depression. Psychoneuroendocrinology. 2015;59:71–80. This study demonstrates that the ∆∆TSH test performed after 2 weeks of antidepressant treatment could be a useful predictor of subsequent clinical outcome.CrossRefPubMedGoogle Scholar
  6. 6.
    Souetre E, Salvati E, Pringuey D, Krebs B, Plasse Y, Darcourt G. The circadian rhythm of plasma thyrotropin in depression and recovery. Chronobiol Int. 1986;3:197–205.CrossRefGoogle Scholar
  7. 7.
    Peteranderl C, Antonijevic IA, Steiger A, Murck H, Held K, Frieboes RM, et al. Nocturnal secretion of TSH and ACTH in male patients with depression and healthy controls. J Psychiatr Res. 2002;36:189–96.CrossRefGoogle Scholar
  8. 8.
    Duval F, Mokrani MC, Crocq MA, Bailey P, Macher JP. Influence of thyroid hormones on morning and evening TSH response to TRH in major depression. Biol Psychiatry. 1994;35:926–34.CrossRefGoogle Scholar
  9. 9.
    Loosen PT, Prange AJ Jr. Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients: a review. Am J Psychiatry. 1982;139:405–16. Scholar
  10. 10.
    • Duval F, Mokrani MC, Erb A, Gonzalez Opera F, Calleja C, Paris V. Relationship between chronobiological thyrotropin and prolactin responses to protirelin (TRH) and suicidal behavior in depressed patients. Psychoneuroendocrinology. 2017;85:100–9. This study suggests that a decreased hypothalamic TRH activity might play key role in the pathogenesis of suicidal behavior.CrossRefPubMedGoogle Scholar
  11. 11.
    Butkute-Sliuoziene K, Berentaite B, Steibliene V. Thyroid axis functioning in patients with high suicide risk. Annals Thyroid Res. 2018;4:141–5.Google Scholar
  12. 12.
    • Peng R, Dai W, Li Y. Low serum free thyroxine level is correlated with lipid profile in depressive patients with suicide attempt. Psychiatry Res. 2018;266:111–5. In this study, patients with a recent history of suicidal behavior exhibit low FT4 levels.CrossRefPubMedGoogle Scholar
  13. 13.
    Alkemade A, Unmehopa UA, Brouwer JP, Hoogendijk WJ, Wiersinga WM, Swaab DF, et al. Decreased thyrotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus of patients with major depression. Mol Psychiatry. 2003;8:838–9. Scholar
  14. 14.
    Alkemade A, Unmehopa UA, Wiersinga WM, Swaab DF, Fliers E. Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus. J Clin Endocrinol Metab. 2005;90:323–927. Scholar
  15. 15.
    Souetre E, Salvati E, Wehr TA, Sack DA, Krebs B, Darcourt G. Twenty-four-hour profiles of body temperature and plasma TSH in bipolar patients during depression and during remission and in normal control subjects. Am J Psychiatry. 1988;145:1133–7. Scholar
  16. 16.
    Duval F, Mokrani MC, Crocq MA, Jautz M, Bailey P, Diep TS, et al. Effect of antidepressant medication on morning and evening thyroid function tests during a major depressive episode. Arch Gen Psychiatry. 1996;53:833–40.CrossRefGoogle Scholar
  17. 17.
    Benedetti F. Antidepressant chronotherapeutics for bipolar depression. Dialogues Clin Neurosci. 2012;14:401–11.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Eravci M, Pinna G, Meinhold H, Baumgartner A. Effects of pharmacological and nonpharmacological treatments on thyroid hormone metabolism and concentrations in rat brain. Endocrinology. 2000;141:1027–40. Scholar
  19. 19.
    Joffe RT, Levitt AJ. The thyroid and depression. In: Joffe RT, Levitt AJ, editors. The thyroid axis and psychiatric illness. Washington: American Psychiatric Press; 1993. p. 195–253.Google Scholar
  20. 20.
    Gendall KA, Joyce PR, Mulder RT, Luty SE. Thyroid indices and response to fluoxetine and nortriptyline in major depression. J Psychopharmacol. 2003;17:431–7. Scholar
  21. 21.
    Gambi F, De Berardis D, Sepede G, Campanella D, Galliani N, Carano A, et al. Effect of mirtazapine on thyroid hormones in adult patients with major depression. Int J Immunopathol Pharmacol. 2005;18:737–44. A good summary of the functions and applications of TRH in mood disorders.CrossRefPubMedGoogle Scholar
  22. 22.
    Nillni EA, Sevarino KA. The biology of pro-thyrotropin-releasing hormone-derived peptides. Endocr Rev. 1999;20:599–648.PubMedGoogle Scholar
  23. 23.
    Kanasaki H, Oride A, Mijiddorj T, Kyo S. Role of thyrotropin-releasing hormone in prolactin-producing cell models. Neuropeptides. 2015;54:73–7. Scholar
  24. 24.
    Gary KA, Sevarino KA, Yarbrough GG, Prange AJ Jr, Winokur A. The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics. J Pharmacol Exp Ther. 2003;305:410–6. Scholar
  25. 25.
    Kamath J, Yarbrough GG, Prange AJ Jr, Winokur A. The thyrotropin-releasing hormone (TRH)-immune system homeostatic hypothesis. Pharmacol Ther. 2009;121(1):20–8. Scholar
  26. 26.
    Post RM, Weiss SR. Ziskind-Somerfeld Research Award 1992. Endogenous biochemical abnormalities in affective illness: therapeutic versus pathogenic. Biol Psychiatry. 1992;32:469–84.CrossRefGoogle Scholar
  27. 27.
    Duval F, Mokrani MC, Bailey P, Correa H, Diep TS, Crocq MA, et al. Thyroid axis activity and serotonin function in major depressive episode. Psychoneuroendocrinology. 1999;24:695–712.CrossRefGoogle Scholar
  28. 28.
    Duval F, Mokrani MC, Lopera FG, Diep TS, Rabia H, Fattah S. Thyroid axis activity and suicidal behavior indepressed patients. Psychoneuroendocrinology. 2010;35:1045–54. Scholar
  29. 29.
    Mann JJ. The serotonergic system in mood disorders and suicidal behaviour. Philos Trans R Soc Lond Ser B Biol Sci. 2013;368:20120537. Scholar
  30. 30.
    Metcalf G. Regulatory peptides as a source of new drugs--the clinical prospects for analogues of TRH which are resistant to metabolic degradation. Brain Res. 1982;257:389–408.CrossRefGoogle Scholar
  31. 31.
    Prange AJ Jr, Lara PP, Wilson IC, Alltop LB, Breese GR. Effects of thyrotropin-releasing hormone in depression. Lancet. 1972;2:999–1002.CrossRefGoogle Scholar
  32. 32.
    Stein D, Avni J. Thyroid hormones in the treatment of affective disorders. Acta Psychiatr Scand. 1988;77:623–36.CrossRefGoogle Scholar
  33. 33.
    Szuba MP, Amsterdam JD, Fernando AT 3rd, Gary KA, Whybrow PC, Winokur A. Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. J Clin Psychopharmacol. 2005;25:325–230.CrossRefGoogle Scholar
  34. 34.
    Marangell LB, George MS, Callahan AM, Ketter TA, Pazzaglia PJ, L'Herrou TA, et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry. 1997;54:214–22.CrossRefGoogle Scholar
  35. 35.
    Thirunarayanan N, Raaka BM, Gershengorn MC. Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor. Front Endocrinol (Lausanne). 2012;3:120. Scholar
  36. 36.
    Khomane KS, Meena CL, Jain R, Bansal AK. Novel thyrotropin-releasing hormone analogs: a patent review. Expert Opin Ther Pat. 2011;21:1673–91. Scholar
  37. 37.
    Prokai-Tatrai K, Nguyen V, Szarka S, Konya K, Prokai L. Design and exploratory neuropharmacological evaluation of novel thyrotropin-releasing hormone analogs and their brain-targeting bioprecursor prodrugs. Pharmaceutics. 2013;5:318–28. Scholar
  38. 38.
    Kubek MJ, Domb AJ, Veronesi MC. Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics. 2009;6:359–71. Scholar
  39. 39.
    Mathews DC, Richards EM, Niciu MJ, Ionescu DF, Rasimas JJ, Zarate CA Jr. Neurobiological aspects of suicide and suicide attempts in bipolar disorder. Transl Neurosci. 2013;4(2).
  40. 40.
    •• Joseph-Bravo P, Jaimes-Hoy L, Uribe RM, Charli JL. 60 years of neuroendocrinology: TRH, the first hypophysiotropic releasing hormone isolated: control of the pituitary-thyroid axis. J Endocrinol. 2015;226:T85–T100. This article reviews the regulations of the thyroid axis.CrossRefPubMedGoogle Scholar
  41. 41.
    Prange AJ Jr, Wilson IC, Knox A, McClane TK, Lipton MA. Enhancement of imipramine by thyroid stimulating hormone: clinical and theoretical implications. Am J Psychiatry. 1970;127:191–9. Up to date systematic review of thyroxine and triiodothyronine use in mood disorders.CrossRefPubMedGoogle Scholar
  42. 42.
    Joffe RT. Hormone treatment of depression. Dialogues Clin Neurosci. 2011;13:127–38.PubMedPubMedCentralGoogle Scholar
  43. 43.
    • Tng EL. The debate on treating subclinical hypothyroidism. Singapore Med J. 2016;57:539–45. This article discusses the rational of treating subclinical hypothyroidism (SCH).CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    • Najafi L, Malek M, Hadian A, Valojerdi AE, Khamesh ME, Aghili R. Depressive symptoms in patients with subclinical hypothyroidism - the effect of treatment with levothyroxine: a double-blind randomized clinical trial. Endocr Res. 2015;40:121–6. This study shows that treating SCH may improve depressive symptoms.CrossRefPubMedGoogle Scholar
  45. 45.
    Kalra S, Balhara YP. Euthyroid depression: the role of thyroid hormone. Recent Pat Endocr Metab Immune Drug Discov. 2014;8:38–41.CrossRefGoogle Scholar
  46. 46.
    Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res. 1990;32:241–51.CrossRefGoogle Scholar
  47. 47.
    Stamm TJ, Lewitzka U, Sauer C, Pilhatsch M, Smolka MN, Koeberle U, et al. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75:162–8. Scholar
  48. 48.
    Chen PH, Huang YJ. Remision of classic rapid cycling bipolar disorder with levothyroxine augmentation therapy in a male patient having clinical hypothyroidism. Neuropsychiatr Dis Treat. 2015.
  49. 49.
    • Bauer M, Berman S, Stamm T, Plotkin M, Adli M, Pilhatsch M, et al. Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study. Mol Psychiatry. 2016;21:229–36. This study demonstrates that administration of supraphysiologic L-T4 improves depressive symptoms in bipolar patients by modulating activity of the anterior limbic network.CrossRefPubMedGoogle Scholar
  50. 50.
    Bauer M, Berghöfer A, Bschor T, Baumgartner A, Kiesslinger U, Hellweg R, et al. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology. 2002;27:620–8.PubMedGoogle Scholar
  51. 51.
    • Walshaw PD, Gyulai L, Bauer M, Bauer MS, Calimlim B, Sugar CA, et al. Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: a double-blind placebo-controlled trial of levothyroxine (L-T4 ) and triiodothyronine (T3). Bipolar Disord. 2018; This study provides evidence for efficacy of L-T4 adjunction in the treatment of rapid cycling bipolar disorder.
  52. 52.
    •• Kelly T. A hypothesis on the mechanism of action of high-dose thyroid in refractory mood disorders. Med Hypotheses. 2016;97:16–21. A good review of the mechanisms of action of thyroid hormones in mood disorders.CrossRefPubMedGoogle Scholar
  53. 53.
    • Pilhatsch M, Berghöfer A, Mayer-Pelinski R, Berghöfer G, Ricken R, Möckel M, et al. Long-term treatment with supraphysiologic doses of levothyroxine in treatment-refractory mood disorders. A prospective study of cardiovascular tolerability. J Affect Disord. 2018;238:213–7. This study shows that T4 is well tolerated.CrossRefPubMedGoogle Scholar
  54. 54.
    Bauer M, Goetz T, Glenn T, Whybrow PC. The thyroid-brain interaction in thyroid disorders and mood disorders. J Neuroendocrinol. 2008;20:1101–14. Scholar
  55. 55.
    Uhl I, Bez JA, Stamm T, Pilhatsch M, Assion HJ, Norra C, et al. Influence of levothyroxine in augmentation therapy for bipolar depression on central serotonergic function. Pharmacopsychiatry. 2014;47:180–3. Scholar
  56. 56.
    Palha JA. Transthyretin as a thyroid hormone carrier: function revisited. Clin Chem Lab Med. 2002;40:1292–300.CrossRefGoogle Scholar
  57. 57.
    Prengel H, Brödel O, Hiedra L, Pinna G, Eravci M, Meinhold H, et al. Effects of tranylcypromine on thyroid hormone metabolism and concentrations in rat brain. Neuropharmacology. 2000;39:99–109.CrossRefGoogle Scholar
  58. 58.
    Papakostas GI, Cooper-Kazaz R, Appelhof BC, Posternak MA, Johnson DP, Klibanski A, et al. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. Int Clin Psychopharmacol. 2009;24:19–25. Scholar
  59. 59.
    Abulseoud OA, Gitlin M, Altshuler L, Frye MA. Baseline thyroid indices and the subsequent response to citalopram treatment, a pilot study. Brain Behav. 2013;3:89–94. Scholar
  60. 60.
    •• Touma KTB, Zoucha AM, Scarff JR. Liothyronine for depression: a review and guidance for safety monitoring. Innov Clin Neurosci. 2017;14:24–9. This is a good review of T3’s mecanism of action, efficacy and safety for the treatment of depression.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Appelhof BC, Brouwer JP, van Dyck R, Fliers E, Hoogendijk WJ, Huyser J, et al. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. J Clin Endocrinol Metab. 2004;89:6271–6. Scholar
  62. 62.
    Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry. 2007;64:679–88. Scholar
  63. 63.
    Garlow SJ, Dunlop BW, Ninan PT, Nemeroff CB. The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. J Psychiatr Res. 2012;46:1406–13. Scholar
  64. 64.
    •• Parmentier T, Sienaert P. The use of triiodothyronine (T3) in the treatment of bipolar depression: a review of the literature. J Affect Disord. 2018;229:410–4. This article reviews the use of T3 as adjunctive treatment for bipolar depression.CrossRefPubMedGoogle Scholar
  65. 65.
    Aronson R. Triiodothyronine augmentation in the treatment of refractory depression. Arch Gen Psychiatry. 1996;53:842–8. Scholar
  66. 66.
    Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163:1519–30. Scholar
  67. 67.
    Lojko R, Rybakowski JK. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. J Affect Disord. 2007;103:253–6. Scholar
  68. 68.
    Kelly TF, Lieberman DZ. Long term augmentation with T3 in refractory major depression. J Affect Disord. 2009;115:230–3. Scholar
  69. 69.
    Rosenthal LJ, Goldner WS, O'Reardon JP. T3 augmentation in major depressive disorder: safety considerations. Am J Psychiatry. 2011;168:1035–40. Scholar
  70. 70.
    • Morin AK. Triiodothyronine (T3) supplementation in major depressive disorder. Mental Health Clinician. 2015;5:253–9. This article is a good review of T3’s efficacy and safety in depression.CrossRefGoogle Scholar
  71. 71.
    Iosifescu DV, Bolo NR, Nierenberg AA, Jensen JE, Fava M, Renshaw PF. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry. 2008;63:1127–34. Scholar
  72. 72.
    Ben-Shlomo A, Melmed S. Hypothalamic regulation of anterior pituitary function. In: Melmed S, editor. The Pituitary. 4th ed. London: Academic Press; 2017. p. 23–45. Scholar
  73. 73.
    Sui L, Ren WW, Li BM. Administration of thyroid hormone increases reelin and brain-derived neurotrophic factor expression in rat hippocampus in vivo. Brain Res. 2010;1313:9–24. Scholar
  74. 74.
    Sabbaghziarani F, Mortezaee K, Akbari M, Kashani IR, Soleimani M, Hassanzadeh G, et al. Stimulation of neurotrophic factors and inhibition of proinflammatory cytokines by exogenous application of triiodothyronine in the rat model of ischemic stroke. Cell Biochem Funct. 2017;35:50–5. Scholar
  75. 75.
    Cooper-Kazaz R, van der Deure WM, Medici M, Visser TJ, Alkelai A, Glaser B, et al. Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J Affect Disord. 2009;116:113–6. Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of PsychiatryCentre HospitalierRouffachFrance

Personalised recommendations